Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.37 |
| ▸ | RIPK1 | Q13546 | 3/20 | 0.37 |
| ▸ | PKM | P14618 | 2/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.36 |
| ▸ | HTR2A | P28223 | 1/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | HTT | P42858 | 2/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | PARK7 | Q99497 | 1/20 | 0.34 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.33 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.33 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.33 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.33 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18688480 | 0.83 | F2RL1 (0.40) | MAPTSMN1; SMN2KCNH2HTR2ALMNA | |
| SCHEMBL13186184 | 0.82 | MAPT (0.37) | MAPTRIPK1PKMSMN1; SMN2KCNH2 | |
| SCHEMBL28982098 | 0.80 | PSEN1 (0.33) | HTR2APSEN1PSEN2APH1BNCSTN | |
| SCHEMBL19121076 | 0.79 | TYR (0.43) | MAPTHTTTP53ALOX15MEN1 | |
| SCHEMBL3667517 | 0.78 | IDO1 (0.40) | MAPTRIPK1PKMSMN1; SMN2KCNH2 | |
| SCHEMBL23680016 | 0.77 | PSEN1 (0.33) | KCNH2HTR2ASLC6A4PSEN1PSEN2 | |
| SCHEMBL15273625 | 0.77 | CA3 (0.34) | MAPTRIPK1SLC6A4TP53ALOX15 | |
| SCHEMBL21383642 | 0.77 | DPP4 (0.33) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL26586563 | 0.77 | IDO1 (0.32) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL13557208 | 0.77 | MAPT (0.37) | MAPTRIPK1PKMSMN1; SMN2KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3263550-B1 | ANILINE DERIVATIVES AND USES THEREOF | NISSAN CHEMICAL CORP (JP) | 2020-11-25 | — | — | EP | disclosed |
| US-9957275-B2 | Pyrazolo[1,5-A]pyrimidines for antiviral treatment | GILEAD SCIENCES, INC. (US) | 2018-05-01 | — | — | US | disclosed |
| US-20170362244-A1 | PYRAZOLO[1,5-A]PYRIMIDINES FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES, INC. | 2017-12-21 | — | — | US | disclosed |
| WO-2010065717-A1 | MORPHOLINONE COMPOUNDS AS FACTOR IXA INHIBITORS | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2010-06-10 | — | — | WO | disclosed |
| US-20090192138-A1 | COMPOUNDS | BAESCHLIN DANIEL KASPAR | 2009-07-30 | — | — | US | disclosed |
| US-20090192138-A1 | COMPOUNDS | BAESCHLIN DANIEL KASPAR | 2009-07-30 | — | — | US | disclosed |
| WO-2007071738-A1 | CONDENSED HETEROCYCLIC COMPOUNDS USEFUL AS DPP-IV INHIBITORS | NOVARTIS AG (CH) | 2007-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170362244-A1 | PYRAZOLO[1,5-A]PYRIMIDINES FOR ANTIVIRAL TREATMENT | TYMP, ZC3HAV1, TYMS | MAPT 3998/4885RIPK1 1186/4885PKM 729/4885 |
| US-20090192138-A1 | COMPOUNDS | DPP4, DPP3, DPP8 | MAPT 2735/4885RIPK1 3431/4885PKM 1790/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.